Diabetes, Vol 30, Issue 1 1-8, Copyright © 1981 by American Diabetes Association

ARTICLES

Tyrosine A14[125I]monoiodoinsulin: Preparation, Biologic Properties, and long-term stability

S Linde, B Hansen, O Sonne, JJ Holst and J Gliemann

125I-insulin was prepared by reacting 17.4 nmol porcine insulin (100 micrograms) with 5 mCi 125I (about 2.4 nmol) using the lactoperoxidase method. The reaction product was subjected to gel electrophoresis and the band containing A14 [125I]monoiodoinsulin was eluted. This preparation showed a specific activity of about 1.5 Ci/mumol as evaluated by radioimmunoassay and bioassay, i.e., about 75% of the theoretical maximum. The content of radioactive derivatives other than A14 monoiodoinsulin was less than 2%. The binding affinity of tracer A14 monoiodoinsulin to adipocytes, hepatocytes, and cultured human lymphocytes was twice as high as that of A19 monoiodoinsulin. Binding to antibodies was examined to 10 guinea pig anti-insulin sera. Three sera did not distinguish between the two tracers, whereas seven exhibited higher binding of the A14 tracer. A detailed analysis of one of the discriminating sera showed that the average affinity constant was about 2.5 times lower for the A19 tracer than for the A14 tracer. The A14 monoiodoinsulin tracer is remarkably stable. After 200 days the specific activity had declined to about half of its original value which is consistent with the hypothesis that the physical decay of [125I]monoiodoinsulin (T 1/2 equals 60 days) extinguishes the activity of the molecule without causing major damage of other molecules. By this time 96% of the radioactivity migrated with insulin when subjected to gel filtration on Sephadex G-50, 4% was in the void volume, and nothing in the total column volume or later. Binding to receptors was indistinguishable from that obtained at time zero. It is concluded that Tyr A14[125I]monoiodoinsulin represents an advance in biologic work as compared with previous tracers for insulin.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Magnusson, O. Melander, B. Israelsson, A. Grubb, L. Groop, and S. Jovinge Elevated Plasma Levels of Nt-proBNP in Patients With Type 2 Diabetes Without Overt Cardiovascular Disease Diabetes Care, August 1, 2004; 27(8): 1929 - 1935. [Abstract] [Full Text] [PDF]

				M. Bucci, F. Roviezzo, V. Brancaleone, M. I. Lin, A. Di Lorenzo, C. Cicala, A. Pinto, W. C. Sessa, S. Farneti, S. Fiorucci, et al. Diabetic Mouse Angiopathy Is Linked to Progressive Sympathetic Receptor Deletion Coupled to an Enhanced Caveolin-1 Expression Arterioscler. Thromb. Vasc. Biol., April 1, 2004; 24(4): 721 - 726. [Abstract] [Full Text] [PDF]

				L. Poulsen Blood pressure and cardiac autonomic function in relation to risk factors and treatment perspectives in Type 1 diabetes Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 222 - 242. [Abstract] [PDF]

				J. C. L. Mamo, G. F. Watts, P. H. R. Barrett, D. Smith, A. P. James, and S. Pal Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression? Am J Physiol Endocrinol Metab, September 1, 2001; 281(3): E626 - E632. [Abstract] [Full Text] [PDF]

				W. R. Kennedy, X. Navarro, and D. E. R. Sutherland Neuropathy profile of diabetic patients in a pancreas transplantation program Neurology, April 1, 1995; 45(4): 773 - 780. [Abstract] [Full Text] [PDF]